Fulgent Genetics Stock Today
| FLGT Stock | USD 20.47 0.42 2.01% |
Performance2 of 100
| Odds Of DistressLess than 9
|
Fulgent Genetics is selling for under 20.47 as of the 7th of October 2024; that is 2.01 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 20.33. Fulgent Genetics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Fulgent Genetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of September 2024 and ending today, the 7th of October 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 29th of September 2016 | Category Healthcare | Classification Health Care |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. The company has 30.3 M outstanding shares of which 723.21 K shares are currently shorted by private and institutional investors with about 6.17 trading days to cover. More on Fulgent Genetics
Moving against Fulgent Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Fulgent Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Ming Hsieh | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, SP Small-Cap 600, NASDAQ Health Care, NASDAQ Composite, Healthcare, Health Care, Health Care Providers & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsFulgent Genetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fulgent Genetics' financial leverage. It provides some insight into what part of Fulgent Genetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fulgent Genetics (FLGT) is traded on NASDAQ Exchange in USA. It is located in 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 and employs 1,184 people. Fulgent Genetics is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 632.9 M. Fulgent Genetics conducts business under Health Care Providers & Services sector and is part of Health Care industry. The entity has 30.3 M outstanding shares of which 723.21 K shares are currently shorted by private and institutional investors with about 6.17 trading days to cover.
Fulgent Genetics currently holds about 515.4 M in cash with 27 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.03.
Check Fulgent Genetics Probability Of Bankruptcy
Ownership AllocationFulgent Genetics holds a total of 30.3 Million outstanding shares. Over half of Fulgent Genetics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Fulgent Ownership Details
Fulgent Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-06-30 | 217.5 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 201.2 K | |
| Citadel Advisors Llc | 2024-06-30 | 186.2 K | |
| Amvescap Plc. | 2024-06-30 | 166.7 K | |
| Jpmorgan Chase & Co | 2024-06-30 | 158.6 K | |
| Barclays Plc | 2024-06-30 | 142.6 K | |
| D. E. Shaw & Co Lp | 2024-06-30 | 132.3 K | |
| Bank Of America Corp | 2024-06-30 | 130.7 K | |
| Invenomic Capital Management, Lp | 2024-06-30 | 125.6 K | |
| Blackrock Inc | 2024-06-30 | 3.9 M | |
| Vanguard Group Inc | 2024-06-30 | 1.4 M |
Fulgent Genetics Historical Income Statement
Fulgent Stock Against Markets
Fulgent Genetics Corporate Management
| Doreen Ng | VP Office | Profile | |
| DABMG FACMG | Chief Director | Profile | |
| Paul Kim | Chief Officer | Profile | |
| Natalie Prescott | General Officer | Profile | |
| Lawrence MD | Chief Officer | Profile |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.